MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Operating Income 2011-2026 | ANIX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.7 M | -13.8 M | -11 M | -13.9 M | -13.1 M | -9.98 M | -11.9 M | -14.3 M | -6.08 M | -4.51 M | -945 K | -5.04 M | -7.92 M | -4.13 M | -5.03 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -945 K | -14.3 M | -8.89 M |
Quarterly Operating Income Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.72 M | - | -2.44 M | -3 M | -3.39 M | - | -3.59 M | -3.47 M | -3.61 M | - | -2.84 M | -2.56 M | -2.56 M | -10.3 M | -2.8 M | -3.59 M | -2.23 M | -9.06 M | -4.39 M | -2.44 M | -2.63 M | -7.74 M | -2.44 M | -2.67 M | -4.98 M | -9.76 M | -2.18 M | -2.59 M | -1.87 M | -8.88 M | -5.61 M | -1.4 M | -1.39 M | -4.34 M | -1.73 M | -1.21 M | -1.47 M | -3.6 M | -975 K | -1.15 M | 3.86 M | 233 K | -1.49 M | -2.13 M | -1.96 M | -3.48 M | -160 K | -1.36 M | -2.07 M | -6.14 M | -2.22 M | -1.85 M | -887 K | -2.41 M | -643 K | -878 K | -1.53 M | -4.02 M | -1.21 M | -1.29 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.86 M | -10.3 M | -2.9 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 15.85 | -2.49 % | $ 171 M |  China |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
1.35 B | $ 115.06 | -0.29 % | $ 35 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.13 | -2.59 % | $ 6.15 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 16.05 | -3.83 % | $ 855 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.3 | - | $ 10.2 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 23.13 | -1.28 % | $ 642 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 175.65 | 0.06 % | $ 8.71 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 493.53 | -1.59 % | $ 14.2 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 189.61 | -1.7 % | $ 135 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 120.93 | -2.22 % | $ 19.2 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.35 | -2.03 % | $ 403 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.43 | -3.93 % | $ 436 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.69 | -3.17 % | $ 985 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 78.6 | -9.83 % | $ 9.85 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B |  Niderland |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.13 | -0.9 % | $ 4.89 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 28.31 | 0.62 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 106.81 | 0.1 % | $ 8.81 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 260.93 | -4.51 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
-541 M | $ 193.03 | -4.91 % | $ 19 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 117.14 | -6.02 % | $ 5.48 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 80.59 | -1.03 % | $ 5.44 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.68 | 0.15 % | $ 279 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.63 | 0.23 % | $ 2.67 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 191.51 | -3.19 % | $ 21.3 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.42 | -6.13 % | $ 2.04 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 4.94 | -6.97 % | $ 3.89 M | USA |
 |
Neuronetics
STIM
|
-31.4 M | $ 1.35 | -2.17 % | $ 89 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 16.48 | -3.34 % | $ 369 M | USA |